Microglial cell membrane-camouflaged nanoparticles for the treatment of ischemic stroke

Cheng Ruiqi, Zhang Rongrong, Qin Xinyue

PDF(3362 KB)
PDF(3362 KB)
Journal of Chongqing Medical University ›› 2024, Vol. 49 ›› Issue (07) : 853-858. DOI: 10.13406/j.cnki.cyxb.003540
Basic research

Microglial cell membrane-camouflaged nanoparticles for the treatment of ischemic stroke

Author information +
History +

Abstract

Objective To prepare MiCM@PFH@Lipid,a multifunctional liposome(Lipid) nanoparticles camouflaged with microglial cell membrane(MiCM) and loaded with the phase change material Perfluorohexane(PFH),to study its basic properties,and to test its ability to specifically target the site of injury after stroke and to achieve revascularization at the site of thrombus. Methods Liposome sphere carriers were prepared by rotary evaporation method. MiCM and PFH were fused with the liposome to form MiCM@PFH@Lipid using the ultrasonic fusion method. Transmission electron microscopy was used to observe the morphology of the nanoparticles. The particle size distribution of nanoparticles at day 1 and their potential distribution at days 1,3,5,and 7 were measured using a Malvern particle size analyzer to detect their stability. Western blot and Coomassie brilliant blue staining were used to detect the encapsulation of nanoparticles with MiCM. The functional state of the mouse brain was detected using brain staining with 2,3,5-triphenyltetrazolium chloride and animal behavior test. Results MiCM@PFH@Lipid nanoparticles were spherical in shape,with a particle size of (234.800±3.143) nm and an average potential of (-33.433±1.550) mV. The nanoparticles were well dispersed and stable within 7 days. MiCM was successfully encapsulated on the nanoparticles. Mouse ex vivo fluorescence image showed that the nanoparticles could rapidly accumulate at the site of injury,which was significantly different as compared with the non-targeted group(P<0.05). Animal behavior test and brain staining showed that MiCM@PFH@Lipid nanoparticles could achieve vascular recanalization and partly restore neurological functions(P<0.05). Pathological examination showed that there was no significant damage to important organs after nanoparticle treatment. Routine blood test showed no significant abnormality as compared with the normal control group(P<0.05). Conclusion In this study,multifunctional nanoparticles(MiCM@PFH@Lipid) were successfully prepared. These nanoparticles can target the injured brain area after ischemic stroke and destroy thrombus,and thus can be used for the treatment of ischemic stroke.

Key words

liposome / microglial cell membrane / perfluorohexane / ischemic stroke

Cite this article

Download Citations
Cheng Ruiqi , Zhang Rongrong , Qin Xinyue. Microglial cell membrane-camouflaged nanoparticles for the treatment of ischemic stroke. Journal of Chongqing Medical University. 2024, 49(07): 853-858 https://doi.org/10.13406/j.cnki.cyxb.003540

References

1
Ding QQ Liu SW Yao YD,et al. Global,regional,and national burden of ischemic stroke,1990-2019[J]. Neurology202298(3):e279-e290.
2
GBD Stroke Collaborators. Global,regional,and national burden of stroke and its risk factors,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet Neurol202120(10):795-820.
3
Jahan R Saver JL Schwamm LH,et al. Association between time to treatment with endovascular reperfusion therapy and outcomes in patients with acute ischemic stroke treated in clinical practice[J]. JAMA2019322(3):252-263.
4
Rajendran R Kunnil A Radhakrishnan A,et al. Current trends and future perspectives for enhanced drug delivery to central nervous system in treatment of stroke[J]. Ther Deliv202314(1):61-85.
5
Huang Y Li M Li JY,et al. The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA:a systematic review[J]. PLoS One20138(6):e65754.
6
Crispo JAG Thibault DP Fortin Y,et al. Association between medication-related adverse events and non-elective readmission in acute ischemic stroke[J]. BMC Neurol201818(1):192.
7
Teleanu DM Chircov C Grumezescu AM,et al. Neuronanomedicine:an up-to-date overview[J]. Pharmaceutics201911(3):101.
8
Sych T Levental KR Sezgin E. Lipid-protein interactions in plasma membrane organization and function[J]. Annu Rev Biophys202251:135-156.
9
Go YK Leal C. Polymer-lipid hybrid materials[J]. Chem Rev2021121(22):13996-14030.
10
Qin C Zhou LQ Ma XT,et al. Dual functions of microglia in ischemic stroke[J]. Neurosci Bull201935(5):921-933.
11
Haynes SE Hollopeter G Yang G,et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides[J]. Nat Neurosci20069(12):1512-1519.
12
Lou NH Takano T Pei Y,et al. Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier[J]. Proc Natl Acad Sci USA2016113(4):1074-1079.
13
Zhong YX Zhang Y Xu J,et al. Low-intensity focused ultrasound-responsive phase-transitional nanoparticles for thrombolysis without vascular damage:a synergistic nonpharmaceutical strategy[J]. ACS Nano201913(3):3387-3403.
14
Ricci S Dinia L Del Sette M,et al. Sonothrombolysis for acute ischaemic stroke[J]. Cochrane Database Syst Rev2012,10:CD008348.
15
Wu HH Jiang XC Li YS,et al. Engineering stem cell derived biomimetic vesicles for versatility and effective targeted delivery[J]. Adv Funct Materials202030(49):2006169.
16
Jin R Zhu XL Li GH. Embolic middle cerebral artery occlusion(MCAO) for ischemic stroke with homologous blood clots in rats[J]. J Vis Exp2014(91):51956.
17
Ruan JS Yao Y. Behavioral tests in rodent models of stroke[J]. Brain Hemorrhages20201(4):171-184.
18
Nisar T Hanumanthu R Khandelwal P. Symptomatic intracerebral hemorrhage after intravenous thrombolysis:predictive factors and validation of prediction models[J]. J Stroke Cerebrovasc Dis201928(11):104360.
19
Sercombe L Veerati T Moheimani F,et al. Advances and challenges of liposome assisted drug delivery[J]. Front Pharmacol20156:286.
20
Camacho-Hernández NP Peña-Ortega F. Fractalkine/CX3CR1-dependent modulation of synaptic and network plasticity in health and disease[J]. Neural Plast20232023:4637073.
21
Paul S Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke:an overview of clinical and preclinical studies[J]. Exp Neurol2021335:113518.

Comments

PDF(3362 KB)

Accesses

Citation

Detail

Sections
Recommended

/